Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Introduction

Residual Ischemic Risk in Patients With Previous MI and Without Prior Stroke or TIA

Outcomes Among Survivors After Acute MI: Real-World Data From the APOLLO Registry

Duration of DAPT in Medically Treated Patients With ACS

Clopidogrel Plus ASA vs ASA Alone for the Prevention of Atherothrombotic Events

DAPT After Drug-Eluting Stents: Results of the DAPT Trial

DAPT After PCI in Patients With and Without Acute MI: Results From the DAPT Trial

PEGASUS-TIMI 54 Trial Design

PEGASUS-TIMI 54: Key Inclusion and Exclusion Criteria

PEGASUS-TIMI 54 Trial Design (cont)

PEGASUS-TIMI 54 Primary Endpoint: Rate of CV Death, MI, or Stroke

PEGASUS-TIMI 54: Components of the Primary Endpoint

PEGASUS-TIMI 54 Safety: Bleeding

Ticagrelor in Patients With Prior MI in the Approved European Label: Data From PEGASUS

Ischemic and Bleeding Outcomes in Patients With Prior MI in the Approved European Label

COMPASS Trial Design

COMPASS Results: Rivaroxaban With or Without ASA in Stable CVD

Putting It All Together: What Do the Data Tell Us?

Putting It All Together: What Do the Data Tell Us? (cont)

Candidates for Long-Term DAPT Post-MI

How Long Should Long-Term DAPT Be Continued Post-MI?

Summary and Conclusions

Abbreviations

Abbreviations (cont)